Update on SARS-CoV-2 seroprevalence - Regional and worldwide.

Abstract Background With limited vaccine supplies, an informed position on the status of SARS-CoV-2 infection in people can assist the prioritization of vaccine deployment. Objective Here, we performed a systematic review and meta-analysis to estimate the global and regional SARS-CoV-2 seroprevalences around the world. Data sources We systematically searched peer-reviewed databases (PubMed, Embase, and Scopus), and preprint servers (medRxiv, bioRxiv, and SSRN) for articles published between 1 January 2020 and 30 March 2021. Study eligibility criteria Population-based studies reporting the SARS-CoV-2 seroprevalence in the general population were included. Participants People of different age groups, occupations, educational levels, ethnic backgrounds and socio-economic status from the general population. Interventions There were no interventions. Methods We used the random-effects meta-analyses and empirical Bayesian method to estimate the pooled seroprevalence and conducted subgroup and meta-regression analyses to explore potential sources of heterogeneity as well as the relationship between seroprevalence and socio-demographics. Results We identified 241 eligible studies involving 6.3 million individuals from 60 countries. The global pooled seroprevalence was 9.47% (95% CI, 8.99%–9.95%), although the heterogeneity among studies was significant (I2 = 99.9%). We estimated that ∼738 million people had been infected with SARS-CoV-2 (as of December 2020). Highest and lowest seroprevalences were recorded in Central & Southern Asia (22.91%, 19.11–26.72%) and Eastern & South-eastern Asia (1.62%, 1.31–1.95%), respectively. Seroprevalence estimates were higher in males, persons aged 20–50 years, in minority ethnic groups living in countries or regions with low income and human development indices. Conclusion The present study indicates that the majority of the world’s human population was still highly susceptible to SARS-CoV-2 infection in mid 2021, emphasizing the need for vaccine deployment to vulnerable groups of people, particularly in developing countries, and for the implementation of enhanced preventive measures until ‘herd immunity’ to SARS-CoV-2 has developed.